File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Significance of hepatitis B virus genotype in liver transplantation for chronic hepatitis B

TitleSignificance of hepatitis B virus genotype in liver transplantation for chronic hepatitis B
Authors
KeywordsMedical sciences
Surgery medical sciences
Allergology and immunology
Issue Date2004
PublisherBlackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/AJT
Citation
The American Transplant Congress 2004 - The 5th Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Boston, MA, 15-19 May 2004. In American Journal of Transplantation, 2004, v. 4 n. suppl. s8, p. 569, abstract no. 1498 How to Cite?
AbstractHepatitis B virus (HBV) genotype influences the disease profile in chronic hepatitis B but its significance in patients who undergo liver transplantation (LTx) is not known. One hundred and nineteen patients with chronic HBV infection who underwent LTx using lamivudine prophylaxis had HBV genotype identifiable from the pre-transplant sera by direct sequencing technique (genotype A, 1; B, 43; C, 74; D, 1). The baseline characteristics and outcome after LTx of patients with genotype B (M:F, 38:5; median [range] age, 45 [17-66] years) were compared to those with genotype C (M:F, 68:6; median [range] age, 49 [21-61] years). More genotype B patients underwent LTx for acute decompensation with flare of HBV ( 15 of 43 Vs 9 of 74; p= 0.003) than genotype C, resulting in a higher serum alanine aminotransferase (58 U/L Vs 40 U/L; p=0.003), serum total bilirubin (426 μmol/L Vs 71 μmol/L); p=0.012), international normalized ratio (2.2 Vs 1.6; p=0.001), and MELD score (34 Vs 18; p=0.004). There were more patients seronegative for HBeAg on listing in genotype B (36 of 41 Vs 41 of 73; p=0.001) than genotype C but the difference in seropositivity for HBVDNA was not significant (26 of 40 Vs 34 of 69; p=0.112). The graft survival at 1, 2, and 3 years after LTx were 93%, 83%, and 83% for genotype B and 100%, 93%, and 89% for genotype C (p=0.2), respectively. Two patients of genotype B and 12 patients of genotype C developed mutants with resistance to lamivudine. The mutant-free survival at 1, 2, and 3 years after LTx were 100%, 100%, and 96% for genotype B and 88%, 82%, and 79% for genotype C (p=0.017), respectively. Liver biopsy taken after the development of mutants showed recurrent hepatitis B in 7 of 10 patients of genotype C, including 2 with fibrosing cholestatic hepatitis and no histologic evidence of hepatitis B in both patients of genotype B. Our data suggest that HBV genotypes B and C are associated with different patterns of end-stage liver disease that required transplantation and genotype C carries a higher risk of recurrence with lamivudine prophylaxis.
DescriptionConcurrent Session 56 - Liver Transplantation: Complications and Disease Recurrence (Non-HCV): abstract no. 1498
Invited Lecture
Persistent Identifierhttp://hdl.handle.net/10722/102495
ISSN
2015 Impact Factor: 5.669
2015 SCImago Journal Rankings: 2.792

 

DC FieldValueLanguage
dc.contributor.authorLo, CMen_HK
dc.contributor.authorCheung, Cen_HK
dc.contributor.authorLau, GKKen_HK
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorLiu, CLen_HK
dc.contributor.authorFan, STen_HK
dc.contributor.authorWong, Jen_HK
dc.date.accessioned2010-09-25T20:32:57Z-
dc.date.available2010-09-25T20:32:57Z-
dc.date.issued2004en_HK
dc.identifier.citationThe American Transplant Congress 2004 - The 5th Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Boston, MA, 15-19 May 2004. In American Journal of Transplantation, 2004, v. 4 n. suppl. s8, p. 569, abstract no. 1498-
dc.identifier.issn1600-6135-
dc.identifier.urihttp://hdl.handle.net/10722/102495-
dc.descriptionConcurrent Session 56 - Liver Transplantation: Complications and Disease Recurrence (Non-HCV): abstract no. 1498-
dc.descriptionInvited Lecture-
dc.description.abstractHepatitis B virus (HBV) genotype influences the disease profile in chronic hepatitis B but its significance in patients who undergo liver transplantation (LTx) is not known. One hundred and nineteen patients with chronic HBV infection who underwent LTx using lamivudine prophylaxis had HBV genotype identifiable from the pre-transplant sera by direct sequencing technique (genotype A, 1; B, 43; C, 74; D, 1). The baseline characteristics and outcome after LTx of patients with genotype B (M:F, 38:5; median [range] age, 45 [17-66] years) were compared to those with genotype C (M:F, 68:6; median [range] age, 49 [21-61] years). More genotype B patients underwent LTx for acute decompensation with flare of HBV ( 15 of 43 Vs 9 of 74; p= 0.003) than genotype C, resulting in a higher serum alanine aminotransferase (58 U/L Vs 40 U/L; p=0.003), serum total bilirubin (426 μmol/L Vs 71 μmol/L); p=0.012), international normalized ratio (2.2 Vs 1.6; p=0.001), and MELD score (34 Vs 18; p=0.004). There were more patients seronegative for HBeAg on listing in genotype B (36 of 41 Vs 41 of 73; p=0.001) than genotype C but the difference in seropositivity for HBVDNA was not significant (26 of 40 Vs 34 of 69; p=0.112). The graft survival at 1, 2, and 3 years after LTx were 93%, 83%, and 83% for genotype B and 100%, 93%, and 89% for genotype C (p=0.2), respectively. Two patients of genotype B and 12 patients of genotype C developed mutants with resistance to lamivudine. The mutant-free survival at 1, 2, and 3 years after LTx were 100%, 100%, and 96% for genotype B and 88%, 82%, and 79% for genotype C (p=0.017), respectively. Liver biopsy taken after the development of mutants showed recurrent hepatitis B in 7 of 10 patients of genotype C, including 2 with fibrosing cholestatic hepatitis and no histologic evidence of hepatitis B in both patients of genotype B. Our data suggest that HBV genotypes B and C are associated with different patterns of end-stage liver disease that required transplantation and genotype C carries a higher risk of recurrence with lamivudine prophylaxis.-
dc.languageengen_HK
dc.publisherBlackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/AJT-
dc.relation.ispartofAmerican Journal of Transplantationen_HK
dc.rightsThe definitive version is available at www.blackwell-synergy.com-
dc.subjectMedical sciences-
dc.subjectSurgery medical sciences-
dc.subjectAllergology and immunology-
dc.titleSignificance of hepatitis B virus genotype in liver transplantation for chronic hepatitis Ben_HK
dc.typeConference_Paperen_HK
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_HK
dc.identifier.emailCheung, C: stcheung@hkucc.hku.hken_HK
dc.identifier.emailLau, GKK: gkklau@netvigator.comen_HK
dc.identifier.emailYuen, MF: mfyuen@hkucc.hku.hken_HK
dc.identifier.emailLiu, CL: clliu@hkucc.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.emailWong, J: jwong@hkucc.hku.hken_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1111/j.1600-6135.2004.0480c.x-
dc.identifier.hkuros91089en_HK
dc.identifier.volume4-
dc.identifier.issuesuppl. s8-
dc.identifier.spage569-
dc.identifier.epage569-
dc.publisher.placeDenmark-
dc.description.otherThe American Transplant Congress 2004 - The 5th Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Boston, MA, 15-19 May 2004. In American Journal of Transplantation, 2004, v. 4 n. suppl. s8, p. 569, abstract no. 1498-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats